Sorry, you need to enable JavaScript to visit this website.

About The Study

On May 10, 2021, the Pfizer & BioNTech COVID-19 vaccine received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for 12 to 15 year-olds.

We are now conducting a study for adolescents 12 to 15 years old that includes a blood test that could help potentially detect and better understand the risk of developing myocarditis (inflammation of the heart muscle) and pericarditis (inflammation of the thin lining around the heart) after receiving the study vaccine. While the chance of having this occur is very low, we want to better understand how to detect this risk in adolescents.

Healthy 12 to 15 year-olds who have not yet been vaccinated may participate. All participants will have the opportunity to receive the COVID-19 vaccine during their time in the study. Participation in the study will last approximately 6 months.

An Important Contribution
 

Today, hundreds of millions of people 12 years and older around the world have received the Pfizer BioNTech COVID-19 vaccine because of the over 46 thousand people who volunteered to be a part of our landmark trial. We are profoundly grateful to them and the thousands of children and their families who are already participating in our COVID-19 Vaccine Pediatric Study.

Joining a clinical trial is an important and personal decision for you and your family. By choosing to join, your child will represent children like them—in age, gender, race, ethnicity, and from communities like yours. We hope it is one you will consider.

Pfizer Logo
BioNTech Logo